X4 Pharmaceuticals (XFOR) Goodwill (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Goodwill for 8 consecutive years, with $17.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Goodwill changed 0.0% year-over-year to $17.4 million; the trailing twelve-month figure through Jun 2026 stood at $17.4 million (changed 0.0% YoY), and the FY2025 full-year result was $17.4 million, changed 0.0% from the prior year.
• Goodwill was little changed at $17.4 million in Q2 2026 per XFOR's latest filing, from $17.4 million in the prior quarter.
• Across five years, Goodwill topped out at $17.4 million in Q1 2022 and bottomed at $17.4 million in Q1 2022.
• Historically, Goodwill has averaged $17.4 million across 5 years, with a median of $17.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Goodwill tumbled 36.0% in 2022, then changed 0.0% in 2023.
• Over 5 years, Goodwill stood at $17.4 million in 2022, then changed by 0.0% to $17.4 million in 2023, then changed by 0.0% to $17.4 million in 2024, then changed by 0.0% to $17.4 million in 2025, then changed by 0.0% to $17.4 million in 2026.
• According to Business Quant data, Goodwill over the past three periods registered $17.4 million, $17.4 million, and $17.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.